Costa SD - Search Results

1

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer.

Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD, Kalinski T. Ignatov A, et al. Among authors: costa sd. Breast Cancer Res Treat. 2011 Jul;128(2):457-66. doi: 10.1007/s10549-011-1584-1. Epub 2011 May 24. Breast Cancer Res Treat. 2011. PMID: 21607586

2

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.

Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M, Costa SD. Eggemann H, et al. Among authors: costa sd. Breast Cancer Res Treat. 2013 Jan;137(2):465-70. doi: 10.1007/s10549-012-2355-3. Epub 2012 Dec 9. Breast Cancer Res Treat. 2013. PMID: 23224235 Clinical Trial.

3

Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer.

Eggemann H, Altmann U, Costa SD, Ignatov A. Eggemann H, et al. Among authors: costa sd. J Cancer Res Clin Oncol. 2018 Feb;144(2):337-341. doi: 10.1007/s00432-017-2539-7. Epub 2017 Nov 2. J Cancer Res Clin Oncol. 2018. PMID: 29098396

4

Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.

Eggemann H, Bernreiter AL, Reinisch M, Loibl S, Taran FA, Costa SD, Ignatov A. Eggemann H, et al. Among authors: costa sd. Br J Cancer. 2019 Feb;120(3):301-305. doi: 10.1038/s41416-018-0369-2. Epub 2019 Jan 17. Br J Cancer. 2019. PMID: 30655614 Free PMC article.

5

Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis.

Eggemann H, Brucker C, Schrauder M, Thill M, Flock F, Reinisch M, Costa SD, Ignatov A. Eggemann H, et al. Among authors: costa sd. Br J Cancer. 2020 Jul;123(1):33-37. doi: 10.1038/s41416-020-0857-z. Epub 2020 May 5. Br J Cancer. 2020. PMID: 32367072 Free PMC article. Clinical Trial.

6

Ultrasonography-guided breast-conserving surgery is superior to palpation-guided surgery for palpable breast cancer.

Eggemann H, Ignatov T, Beni A, Costa SD, Ignatov A. Eggemann H, et al. Among authors: costa sd. Clin Breast Cancer. 2014 Feb;14(1):40-5. doi: 10.1016/j.clbc.2013.08.016. Epub 2013 Oct 26. Clin Breast Cancer. 2014. PMID: 24169374

7

GPER functions as a tumor suppressor in triple-negative breast cancer cells.

Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z, Ignatov A. Weißenborn C, et al. Among authors: costa sd. J Cancer Res Clin Oncol. 2014 May;140(5):713-23. doi: 10.1007/s00432-014-1620-8. Epub 2014 Feb 20. J Cancer Res Clin Oncol. 2014. PMID: 24553912

8

Accuracy of ultrasound-guided breast-conserving surgery in the determination of adequate surgical margins.

Eggemann H, Ignatov T, Costa SD, Ignatov A. Eggemann H, et al. Among authors: costa sd. Breast Cancer Res Treat. 2014 May;145(1):129-36. doi: 10.1007/s10549-014-2932-8. Epub 2014 Mar 29. Breast Cancer Res Treat. 2014. PMID: 24682656 Clinical Trial.

9

Clinical implications of growth pattern and extension of tumor-associated intraductal carcinoma of the breast.

Eggemann H, Kalinski T, Ruhland AK, Ignatov T, Costa SD, Ignatov A. Eggemann H, et al. Among authors: costa sd. Clin Breast Cancer. 2015 Jun;15(3):227-33. doi: 10.1016/j.clbc.2014.11.008. Epub 2014 Dec 2. Clin Breast Cancer. 2015. PMID: 25516401

10

Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.

Ignatov T, Eggemann H, Burger E, Fettke F, Costa SD, Ignatov A. Ignatov T, et al. Among authors: costa sd. Breast Cancer Res Treat. 2015 Jun;151(2):357-64. doi: 10.1007/s10549-015-3407-2. Epub 2015 Apr 30. Breast Cancer Res Treat. 2015. PMID: 25926338

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters